Novartis puts generic epinephrine shots up for sale in U.S.

July 9, 2019

Novartis’ Sandoz unit have made its Symjepi epinephrine shots immediately available in local U.S. pharmacies amid a continuing EpiPen shortage in the United States, Europe and Canada. Both the adult and pediatric doses of the drug will be available. Symjepi launched for use in hospitals back in January.

According to Novartis, the wholesale price for a two-pack of adult-dose syringes is $250, which is below the $300 charged by Mylan and Teva.

The U.S. Food and Drug Administration added the EpiPens to its list of drugs in shortage more than a year ago.

Pfizer’s Meridian, which produces all EpiPens sold globally at a single plant, has been hit by a series of manufacturing problems and continues to anticipate more shortages for the coming months.

Read the Reuters report